The use of anxiolytic medicines in Sweden has displayed a consistent decline from 2013 to 2023, where the consumption stood at 9.5 Units (Defined Daily Dosage) Per Thousand Persons Per Day. The past decade shows varying rates of reduction with notable year-on-year declines such as -7.97% in 2017 and -6.54% in 2021. The Compound Annual Growth Rate (CAGR) over the past five years up to 2023 averages at -4.4%. Looking forward, the forecasted data indicates a further gradual decrease in anxiolytic use, with the consumption expected to reach 8.3 Units by 2028. The forecasted five-year CAGR stands at -2.04%, reflecting a slower decline compared to the past period.

Future trends to monitor include:

Shifts in medical guidelines and prescribing practices towards non-pharmacological anxiety management.
Public health initiatives and awareness campaigns emphasizing mental wellness and alternative treatments.
Socioeconomic factors and new research influencing the public perception and use of anxiolytic medications.